$KNW
KNOW LABS, INC. Stock $knw

$knw Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000165495423015760 Filed on December 19, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.011M	$789.1K	$6.571M
YoY Change	5.57%		-19.06%
% of Gross Profit
Research & Development	$1.486M	$1.541M	$7.727M
YoY Change	-14.72%		43.48%
% of Gross Profit
Depreciation & Amortization	$18.72K	$53.48K	$313.0K
YoY Change	-81.85%		-2.48%
% of Gross Profit
Operating Expenses	$3.498M	$2.330M	$14.02M
YoY Change	-4.13%		-17.18%
Operating Profit	-$3.498M		-$14.02M
YoY Change	-4.13%		11.53%
Interest Expense	$0.00	$12.82K	$389.6K
YoY Change	-100.0%		-95.14%
% of Operating Profit
Other Income/Expense, Net	$51.01K	-$364.6K	-$1.265M
YoY Change	-129.19%		-83.13%
Pretax Income	-$3.447M	-$2.936M	-$15.29M
YoY Change	-9.84%		-23.83%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.447M	-$3.125M	-$15.29M
YoY Change	-9.84%		-23.83%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.04	-$0.06	-$0.41
COMMON SHARES
Basic Shares Outstanding	81.35M shares	52.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.821M	$8.024M	$8.024M
YoY Change	-50.19%		-36.29%
Cash & Equivalents	$4.821M	$8.024M	$8.024M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.821M	$8.024M	$8.024M
YoY Change	-50.19%	-36.29%	-36.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$75.30K	$81.33K	$226.4K
YoY Change	-90.23%	-90.58%	-80.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.77K	$15.77K	$15.77K
YoY Change	19.02%		14.52%
Total Long-Term Assets	$191.6K	$242.2K	$242.2K
YoY Change	-81.39%	-79.21%	-79.21%
TOTAL ASSETS
Total Short-Term Assets	$4.821M	$8.024M	$8.024M
Total Long-Term Assets	$191.6K	$242.2K	$242.2K
Total Assets	$5.013M	$8.266M	$8.266M
YoY Change	-53.19%	-39.92%	-39.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$627.1K	$1.293M	$1.293M
YoY Change	54.98%		145.34%
Accrued Expenses	$95.95K	$94.06K	$467.2K
YoY Change	-79.36%	-79.68%	-54.49%
Deferred Revenue
YoY Change
Short-Term Debt	$2.762M	$2.762M	$2.762M
YoY Change	22.48%		22.48%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.787M	$4.522M	$4.522M
YoY Change	3.53%	18.73%	18.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.787M	$4.522M	$4.522M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.787M	$4.522M	$4.522M
YoY Change	2.25%	16.07%	16.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$125.4M	-$121.8M
YoY Change	19.13%	20.16%
Common Stock	$81.35K	$80.36K
YoY Change	68.74%	66.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.226M	$3.744M	$3.744M
YoY Change
Total Liabilities & Shareholders Equity	$5.013M	$8.266M	$8.266M
YoY Change	-53.19%	-39.92%	-39.92%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$3.447M	-$3.125M	-$15.29M
YoY Change	-9.84%		-23.83%
Depreciation, Depletion And Amortization	$18.72K	$53.48K	$313.0K
YoY Change	-81.85%		-2.48%
Cash From Operating Activities	-$3.393M	-$1.378M	-$10.35M
YoY Change	16.29%		49.63%
INVESTING ACTIVITIES
Capital Expenditures	$12.70K	$0.00	$80.80K
YoY Change	17.02%		-90.56%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$12.70K	$0.00	-$80.80K
YoY Change	17.07%		-90.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$203.1K	5.473M	$5.865M
YoY Change	1268.36%		-27.69%
NET CHANGE
Cash From Operating Activities	-$3.393M	-1.378M	-$10.35M
Cash From Investing Activities	-$12.70K	0.000	-$80.80K
Cash From Financing Activities	$203.1K	5.473M	$5.865M
Net Change In Cash	-$3.202M	4.095M	-$4.570M
YoY Change	9.91%		-1462.24%
FREE CASH FLOW
Cash From Operating Activities	-$3.393M	-$1.378M	-$10.35M
Capital Expenditures	$12.70K	$0.00	$80.80K
Free Cash Flow	-$3.405M	-$1.378M	-$10.43M
YoY Change	16.29%		34.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001074828
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80358463	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48156062	shares
CY2023Q3	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	80358463	shares
CY2023Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	213330	usd
CY2022Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1510265	usd
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3612	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	21366	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	26855	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	153371	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	677755	usd
CY2023Q3	knwn	Total Remaining Payments TotalRemainingPayments	153401	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1396	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	154797	usd
CY2023	knwn	Stock Option Expiry Term StockOptionExpiryTerm	P5Y
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37479
CY2023	dei	Entity Registrant Name EntityRegistrantName	KNOW LABS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0273142
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Union Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 810
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Seattle
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98101
CY2023	dei	City Area Code CityAreaCode	206
CY2023	dei	Local Phone Number LocalPhoneNumber	903-1351
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	KNW
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	32309758	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	81346524	shares
CY2023	dei	Auditor Firm AuditorFirmId	207
CY2023	dei	Auditor Name AuditorName	BPM LLP
CY2023	dei	Auditor Location AuditorLocation	Walnut Creek, California
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8023716	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12593692	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	8023716	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	12593692	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	81325	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	862977	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	15766	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	13767	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	145090	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	287930	usd
CY2023Q3	us-gaap	Assets Assets	8265897	usd
CY2022Q3	us-gaap	Assets Assets	13758366	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1292861	usd
CY2022Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	526968	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	94062	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	462940	usd
CY2023Q3	knwn	Amount Due To Related Parties Current AmountDueToRelatedPartiesCurrent	218334	usd
CY2022Q3	knwn	Amount Due To Related Parties Current AmountDueToRelatedPartiesCurrent	348264	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2761931	usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2255066	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	154797	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	215397	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4521985	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3808635	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87118	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	87118	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80358463	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48156062	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	80358	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	48158	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125501537	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	111209388	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121840788	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101397738	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	3743912	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9862613	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8265897	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13758366	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Revenues Revenues	4360087	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7727467	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5385586	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6570597	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8118137	usd
CY2023	us-gaap	Selling Expense SellingExpense	274019	usd
CY2022	us-gaap	Selling Expense SellingExpense	3430438	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	14024045	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	16934161	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-14024045	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12574074	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	127145	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	15283	usd
CY2023	us-gaap	Interest Expense InterestExpense	389626	usd
CY2022	us-gaap	Interest Expense InterestExpense	8034081	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-506865	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Other Income OtherIncome	-495776	usd
CY2022	us-gaap	Other Income OtherIncome	521628	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1265122	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7497170	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15289167	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20071244	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-15289167	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20071244	usd
CY2023	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	1627230	usd
CY2022	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	0	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3526653	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2023	knwn	Net Income Loss Available To Common Stockholders NetIncomeLossAvailableToCommonStockholders	-20443050	usd
CY2022	knwn	Net Income Loss Available To Common Stockholders NetIncomeLossAvailableToCommonStockholders	-20071244	usd
CY2023	knwn	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.41
CY2022	knwn	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.50
CY2023	knwn	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	49581467	shares
CY2022	knwn	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	40370473	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1242163	usd
CY2022	knwn	Stock Compensation Expense Employee Options StockCompensationExpenseEmployeeOptions	4421634	usd
CY2022	knwn	Conversion Of Debt Offering And Accrued Interest Amount ConversionOfDebtOfferingAndAccruedInterestAmount	15345720	usd
CY2022	knwn	Issuance Of Common Stock For Stock Option Exercises Amount IssuanceOfCommonStockForStockOptionExercisesAmount	26687	usd
CY2022	knwn	Issuance Of Common Stock For Exercise Of Warrants Amount IssuanceOfCommonStockForExerciseOfWarrantsAmount	838487	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	183000	usd
CY2022	knwn	Issuance Of Common Stock Warrant For Services IssuanceOfCommonStockWarrantForServices	451487	usd
CY2022	knwn	Isssuance Of Common Stock For Nyse Uplisting Amount IsssuanceOfCommonStockForNyseUplistingAmount	7424679	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20071244	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9862613	usd
CY2023	knwn	Stock Compensation Expense Employee Options StockCompensationExpenseEmployeeOptions	2955933	usd
CY2023	knwn	Issuance Of Common Stock For Stock Option Exercises Amount IssuanceOfCommonStockForStockOptionExercisesAmount	4687	usd
CY2023	knwn	Issuance Of Common Stock For Exercise Of Warrants Amount IssuanceOfCommonStockForExerciseOfWarrantsAmount	387334	usd
CY2023	knwn	Common Stock Dividends On Series D Preferred Stock Amount CommonStockDividendsOnSeriesDPreferredStockAmount	0	usd
CY2023	knwn	Deemed Dividends On Series C And D Preferred Stock DeemedDividendsOnSeriesCAndDPreferredStock	0	usd
CY2023	knwn	Isssuance Of Common Stock For Common Stock Offering Amount IsssuanceOfCommonStockForCommonStockOfferingAmount	5472791	usd
CY2023	knwn	Expenses For Extension Of Notes And Warrants ExpensesForExtensionOfNotesAndWarrants	349721	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-15289167	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	3743912	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-15289167	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-20071244	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	313019	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	320995	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	183000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	451487	usd
CY2023	knwn	Gain Loss On Debt Settlement GainLossOnDebtSettlement	-50000	usd
CY2022	knwn	Gain Loss On Debt Settlement GainLossOnDebtSettlement	-268872	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	549431	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	506865	usd
CY2022	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	usd
CY2023	us-gaap	Interest Expense Foreign Deposits InterestExpenseForeignDeposits	349721	usd
CY2022	us-gaap	Interest Expense Foreign Deposits InterestExpenseForeignDeposits	0	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2955933	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	4421634	usd
CY2023	knwn	Gain Loss On Forgiveness Of Notes Payable Ppp Loans GainLossOnForgivenessOfNotesPayablePppLoans	0	usd
CY2022	knwn	Gain Loss On Forgiveness Of Notes Payable Ppp Loans GainLossOnForgivenessOfNotesPayablePppLoans	-252700	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	142840	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	35963	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7272911	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1999	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-147719	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22917	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	317085	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1009935	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10353991	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6919808	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	80797	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	855468	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80797	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-855468	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8280000	usd
CY2023	knwn	Proceeds From Issuance Of Common Stock Offering Net ProceedsFromIssuanceOfCommonStockOfferingNet	5472791	usd
CY2022	knwn	Proceeds From Issuance Of Common Stock Offering Net ProceedsFromIssuanceOfCommonStockOfferingNet	0	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	855321	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	179103	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4687	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26687	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	387334	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	838487	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5864812	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8110750	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4569976	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	335474	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12593692	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12258218	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8023716	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12593692	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	14209000	usd
CY2023	knwn	Conversion Of Accrued Interest ConversionOfAccruedInterest	0	usd
CY2022	knwn	Conversion Of Accrued Interest ConversionOfAccruedInterest	1136720	usd
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	1627230	usd
CY2022	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2023	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	3526653	usd
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	0	usd
CY2023	knwn	Issuance Costs From Common Stock Offering IssuanceCostsFromCommonStockOffering	1527209	usd
CY2022	knwn	Issuance Costs From Common Stock Offering IssuanceCostsFromCommonStockOffering	0	usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q3	knwn	Authorized Shares Of Capital Stock AuthorizedSharesOfCapitalStock	205000000	shares
CY2023Q3	knwn	Authorized Shares Of Capital Common Stock AuthorizedSharesOfCapitalCommonStock	200000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	knwn	Authorized Common Stock Increased AuthorizedCommonStockIncreased	200000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	knwn	Cash And Cash Equivalents CashAndCashEquivalents	8023716	usd
CY2023Q3	knwn	Net Working Capital NetWorkingCapital	6262662	usd
CY2023Q3	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	usd
CY2023	us-gaap	Revenue Recognition Leases RevenueRecognitionLeases	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Revenue Recognition</em></strong><strong> </strong>– The Company determines revenue recognition from contracts with customers through the following steps:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">identification of the contract, or contracts, with the customer;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">identification of the performance obligations in the contract;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">determination of the transaction price;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">allocation of the transaction price to the performance obligations in the contract; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recognition of the revenue when, or as, the Company satisfies a performance obligation.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. During the three months ended December 31, 2021, the Company generated revenue from digital asset sales of NFTs. The Company engineering team, using its research data, AI and proprietary algorithms, produced NFTs in the form of digital art. The NFTs produced had no recorded cost basis. The Company does not expect future activity or revenue from that source.</p>
CY2022Q3	knwn	Outstanding At Begenning Of Period OutstandingAtBegenningOfPeriod	1.029
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	980000	shares
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7727467	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5385586	usd
CY2023	knwn	Severance And Other Expenses SeveranceAndOtherExpenses	859000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	305292	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	379724	usd
CY2023Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	7836393	usd
CY2022Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11821931	usd
CY2023	us-gaap	Derivatives Methods Of Accounting Hedge Effectiveness DerivativesMethodsOfAccountingHedgeEffectiveness	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Derivative Financial Instruments</em></strong><strong> – </strong>Pursuant to ASC 815 “Derivatives and Hedging”, the Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company then determines if an embedded derivative must be bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company determined that the conversion features for purposes of bifurcation within its convertible notes payable issued during 2020 and 2021 were immaterial and as of September 30, 2023 all such convertible notes have been converted to common stock and there was no derivative liability. </p>
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.250
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2582727	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.250
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	297273	shares
CY2023	knwn	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice	0.250
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80358463	shares
CY2023Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	14506158	shares
CY2023	knwn	Convertible Debentures ConvertibleDebentures	2761931	usd
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48156062	shares
CY2022Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	20792370	shares
CY2022	knwn	Convertible Debentures ConvertibleDebentures	2255066	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates</em></strong> – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023	us-gaap	Depreciation Depreciation	313019	usd
CY2022	us-gaap	Depreciation Depreciation	320995	usd
CY2023Q3	knwn	Assets Net Book Value AssetsNetBookValue	549431	usd
CY2023Q3	knwn	Total Lease Liability TotalLeaseLiability	155000	usd
CY2022Q3	knwn	Total Lease Liability TotalLeaseLiability	303000	usd
CY2023Q3	knwn	Right Of Use Assets RightOfUseAssets	145000	usd
CY2022Q3	knwn	Right Of Use Assets RightOfUseAssets	288000	usd
CY2023	us-gaap	Lease Cost LeaseCost	268000	usd
CY2022	us-gaap	Lease Cost LeaseCost	289000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07	pure
CY2023Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	94062	usd
CY2022Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	86562	usd
CY2023	us-gaap	Equipment Expense EquipmentExpense	230005	usd
CY2022	knwn	Amortization Of Debt Discount Premiums AmortizationOfDebtDiscountPremiums	7272911	usd
CY2023Q3	knwn	Convertible Notes Conversions ConvertibleNotesConversions	0	usd
CY2022Q3	knwn	Convertible Notes Conversions ConvertibleNotesConversions	-14209000	usd
CY2023Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	2761931	usd
CY2022Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	2255066	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	7684381	shares
CY2022	knwn	Description Of Automatic Conversion Of Convertible DescriptionOfAutomaticConversionOfConvertible	The Company issued 7,672,860 shares of common stock related to the automatic conversion of convertible notes and interest from a private placement to accredited investors in 2021. The convertible notes and interest were automatically converted to common stock at $2.00 per share on the one-year anniversary in March 2022
CY2022	knwn	Shrare Issued Warrant To Purchased Price ShrareIssuedWarrantToPurchasedPrice	1.749
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	194019	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	244260	usd
CY2022Q3	knwn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbers ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers	21786313	shares
CY2023	knwn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Numbe ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe	20886313	shares
CY2023Q3	knwn	Outstanding At End Of Period OutstandingAtEndOfPeriod	1.103
CY2023Q3	knwn	Exercisable At End Of Period ExercisableAtEndOfPeriod	20886313	shares
CY2023Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	20886313	shares
CY2023	knwn	Weighted Averages Remaining Life Years WeightedAveragesRemainingLifeYears	P2Y25D
CY2023Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.163
CY2023Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	20886313	shares
CY2023Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	1.163
CY2023	srt	Federal Funds Sold Average Yield FederalFundsSoldAverageYield	0	pure
CY2023	knwn	Expected Life Minimum ExpectedLifeMinimum	P3Y
CY2023	knwn	Expected Life Maximum ExpectedLifeMaximum	P5Y
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	1.04	pure
CY2023	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.0296	pure
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	20866313	usd
CY2023	knwn	Sharebased Compensation Arrangements By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	0	usd
CY2023	knwn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Unearned ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned	4158333	shares
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.381
CY2023	knwn	Stock Issued During Period Shares Stock Option Exercised StockIssuedDuringPeriodSharesStockOptionExercised	166890	shares
CY2022Q3	knwn	Warrant Issued To Common Stock WarrantIssuedToCommonStock	26293	shares
CY2022Q3	knwn	Exercise Stock Option Grantsreceived ExerciseStockOptionGrantsreceived	26887	usd
CY2023	knwn	Stock Option Grants StockOptionGrants	14906158	shares
CY2023	knwn	Intrinsic Value IntrinsicValue	0	usd
CY2023	knwn	Lease Description LeaseDescription	pursuant to which Mr. Bosua is entitled receive a $400,000 severance payment and benefits pursuant to his prior employment agreement. Pursuant to the Separation Agreement, Mr. Bosua’s outstanding stock options ceased vesting as of January 23, 2023, and all vested stock options remain exercisable through January 23, 2024. Mr. Bosua has been engaged as a consultant to the Company for a period of one year at a rate of $10,000 per month. Mr. Bosua also entered into a lock up and leak out agreement with respect to 3,005,000 common shares owned by Mr. Bosua and shares issuable upon exercise of his vested option awards. During the period commencing March 17, 2023 through March 17, 2024, Mr. Bosua may sell no more than 1,500,000 shares. During the period commencing April 1, 2024 through June 30, 2026, Mr. Bosua may sell no more than 375,000 shares per quarter (or 1,500,000 shares per year), unless the stock price of the Company’s common stock exceeds $5.00 per share on the NYSE American (the “Stock Price Threshold”), then Mr. Bosua may sell a maximum of 750,000 shares during any such quarter that the Stock Price Threshold is met. Notwithstanding the foregoing, any lock-up or leak-out restrictions are waived for any sales of shares from Mr. Bosua to Todd Baszucki.
CY2017Q2	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	3334	usd
CY2023	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	2986	usd
CY2023Q2	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	2908	usd
CY2021Q2	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	8697	usd
CY2021Q2	knwn	Lease Description LeaseDescription	increases by 3% annually. The lease expires on June 30, 2024. The lease can be extended for one additional three-year term
CY2021Q4	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	5000	usd
CY2022Q3	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	7000	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	91500	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	28000	usd
CY2022Q4	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	2250	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	49500000	usd
CY2023	knwn	Federal Net Operating Loss Carryforwards Expired FederalNetOperatingLossCarryforwardsExpired	expire in 2028-2042
CY2023	knwn	Effective Tax Rate EffectiveTaxRate	1	pure
CY2023Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14200000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11400000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10476000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9372000	usd
CY2023Q3	knwn	Deferred Tax Assets Operating Loss Carryforwards Stock Based Compensation DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation	2174000	usd
CY2022Q3	knwn	Deferred Tax Assets Operating Loss Carryforwards Stock Based Compensation DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation	1677000	usd
CY2023Q3	knwn	Deferred Tax Assets Operating Loss Carryforwards Research And Development DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment	1460000	usd
CY2022Q3	knwn	Deferred Tax Assets Operating Loss Carryforwards Research And Development DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment	0	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	221000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	46000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	97000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14156000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11367000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14156000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11367000	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2789000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1666000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.01	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.12	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.18	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.07	pure
CY2023	knwn	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Other And Prior Year True Up EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp	0.02	pure
CY2022	knwn	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Other And Prior Year True Up EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp	0.02	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	knwn	Segment Revenues SegmentRevenues	0	usd
CY2023	knwn	Segment Net Income Loss SegmentNetIncomeLoss	-14024000	usd
CY2023	knwn	Segment Asset SegmentAsset	8266	usd
CY2022	knwn	Segment Revenues SegmentRevenues	4360	usd
CY2022	knwn	Segment Net Income Loss SegmentNetIncomeLoss	-12574000	usd
CY2022	knwn	Segment Asset SegmentAsset	13758	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	4767809	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	12164418	usd
CY2023Q3	knwn	Stock Option Grants To Employees And Directors StockOptionGrantsToEmployeesAndDirectors	13909315	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.256

Files In Submission

Name	View Source	Status
0001654954-23-015760-index-headers.html	Edgar Link	pending
0001654954-23-015760-index.html	Edgar Link	pending
0001654954-23-015760.txt	Edgar Link	pending
0001654954-23-015760-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
knwn-20230930.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
knwn_10k.htm	Edgar Link	pending
knwn_10kimg32.jpg	Edgar Link	pending
knwn_10kimg33.jpg	Edgar Link	pending
knwn_ex211.htm	Edgar Link	pending
knwn_ex231.htm	Edgar Link	pending
knwn_ex311.htm	Edgar Link	pending
knwn_ex312.htm	Edgar Link	pending
knwn_ex321.htm	Edgar Link	pending
knwn_ex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
knwn-20230930_cal.xml	Edgar Link	unprocessable
knwn-20230930_def.xml	Edgar Link	unprocessable
knwn-20230930_lab.xml	Edgar Link	unprocessable
knwn_10k_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
knwn-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KNW
KNOW LABS, INC. Stock $knw

2023 Q4 Form 10-K Financial Statement

#000165495423015760 Filed on December 19, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KNW KNOW LABS, INC. Stock $knw

2023 Q4 Form 10-K Financial Statement

#000165495423015760 Filed on December 19, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KNW
KNOW LABS, INC. Stock $knw